NewEdge Wealth LLC Acquires Shares of 6,309 Edwards Lifesciences Corporation $EW

NewEdge Wealth LLC acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 6,309 shares of the medical research company’s stock, valued at approximately $571,000.

A number of other institutional investors have also recently bought and sold shares of the business. Great Lakes Advisors LLC bought a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at $1,255,000. BOK Financial Private Wealth Inc. bought a new position in shares of Edwards Lifesciences in the 2nd quarter worth $1,096,000. Danske Bank A S bought a new position in shares of Edwards Lifesciences in the 2nd quarter worth $47,445,000. Diversify Advisory Services LLC acquired a new stake in shares of Edwards Lifesciences during the second quarter worth $419,000. Finally, Wealthfront Advisers LLC acquired a new stake in shares of Edwards Lifesciences during the second quarter worth $3,630,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Citigroup upped their price objective on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $87.00 to $101.00 in a research report on Friday, July 24th. Royal Bank Of Canada boosted their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Evercore reaffirmed an “outperform” rating and issued a $100.00 price target on shares of Edwards Lifesciences in a research note on Monday, July 6th. Finally, Mizuho increased their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Seventeen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $89.89 on Friday. The company has a market capitalization of $51.76 billion, a PE ratio of 51.66, a PEG ratio of 2.26 and a beta of 0.85. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The stock’s fifty day simple moving average is $89.21 and its 200 day simple moving average is $84.67.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. During the same period in the previous year, the company posted $0.67 earnings per share. The company’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, research analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the sale, the vice president directly owned 40,034 shares in the company, valued at $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the sale, the senior vice president directly owned 15,334 shares in the company, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 25,570 shares of company stock worth $2,219,390 over the last ninety days. Company insiders own 0.31% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.